




PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48		A1	(11) International Publication Number: WO 95/03829
			(43) International Publication Date: 9 February 1995 (09.02.95)
(21) International Application Number: PCT/EP94/02577 (22) International Filing Date: 3 August 1994 (03.08.94) (30) Priority Data: 106578 3 August 1993 (03.08.93) IL (71) Applicants (for all designated States except US): YISSUM, RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; 46 Jabotinsky Street, Jerusalem (IL). BENEDUM, Ulrich, Max [DE/DE]; Ina-Seidel-Bogen 42, D-81929 München (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): MAGDASSI, Shlomo [IL/IL]; 36 Haner Street, Jerusalem (IL). RONES, Zichria, Zakay [IL/IL]; 52/A Hapalmach Street, Jerusalem (IL). LINEVITZ, Moshe [IL/IL]; 43 Hahil Street, Ramat Gan (IL). SHANBERG, Oren [IL/IL]; 13 Kubelski Street, Bnei Brak (IL). (74) Agents: HASELTINE LAKE PARTNERS; Rosenheimer Strasse 30, D-81669 München (DE) et al.		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	

(54) Title: A METHOD AND PHARMACEUTICAL COMPOSITIONS FOR DRUG TARGETING



(57) Abstract

A pharmaceutical composition comprising an oil/water emulsion wherein the oil droplets contain a drug in dissolved or dispersed or solubilized form. The droplets are further coated with adsorbed native or modified antibodies which provide targeting of the droplets and the drug. The process for preparing this composition comprises the steps of (i) dissolving or dispersing a drug in an oil phase, (ii) preparing an oil/water emulsion, (iii) obtaining surface-active antibodies by chemical or physical attachment of hydrophobic groups to the antibodies, and (iv) mixing the surface-active antibody with the emulsion.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

A METHOD AND PHARMACEUTICAL COMPOSITIONS FOR DRUG TARGETING

The present invention relates to pharmaceutical compositions and a method for drug targeting. More specifically said invention relates to pharmaceutical compositions containing an oil/water emulsion wherein a drug is dissolved or solubilized or dispersed inside the oil droplets and wherein said emulsion droplets are coated with adsorbed native and modified antibodies. The invention relates also to a process for the preparation of said pharmaceutical compositions and to a method for drug targeting toward specific molecules or sites in the body, comprising administration to a host an effective amount of above mentioned pharmaceutical compositions.

Emulsion droplets are coated with adsorbed native and/or modified antibodies which are capable of interacting with specific molecules or antigenic determinants. Therefore, the droplets will be directed towards specific molecules or sites in the body. When a drug is dissolved, dispersed or solubilized inside the oil droplet, a novel drug targeting system is obtained.

Background of the Invention

The present invention relates to drug targeting by small emulsion droplets, using biologically active targeting molecules. The advantages of being able to direct the drug to the tissue or cells where it is required, and to minimize the amount delivered to inappropriate sites has implications for many clinical situations, such as cancer chemotherapy, inflammations and viral infections (Davis S.S et al. Drug Exptl. Clin. Res. 2, 632, 1985).

In the past, several attempts to achieve drug targeting were reported, by using polyclonal and monoclonal antibodies. These attempts include:-

1. Direct chemical attachment of drug molecules to an antibody molecule.

2. Chemical attachment of drugs to antibodies through the use of a linkage polymer molecule such as dextran.

5 3. Attachment of small antibodies to small biodegradable polymeric particles, by covalent linkage by direct adsorption or by adsorption via protein A.

4. Coupling of liposomes with monoclonal antibodies via hydrophobic modification of the antibody.

10 The above suggested method to achieve drug targeting have many disadvantages:-

a) Covalent attachment of drug molecules require development of a chemical binding process for each drug to be tested.

15 b) Direct attachment to the antibody may reduce its biological activity.

c) Only a limited amount of drug molecules may be bound.

d) The clinical effects of the drugs may be altered upon chemical attachment.

20 e) Possible leakage of drugs if liposomes are used.

f) Desorption of the antibodies may occur if it is physically adsorbed to a solid particle.

25 The present invention will provide a novel drug targeting method, which would overcome most of the above disadvantages, by the use of emulsions and micro emulsions.

Brief Description of the Invention

30 The present invention relates to pharmaceutical compositions containing an oil/water emulsion wherein a drug is dissolved or dispersed or solubilized inside the oil droplets and wherein said emulsion droplets are coated with adsorbed native and/or modified antibodies.

35 The present invention further relates to a process for the preparation of said pharmaceutical compositions comprising:-

- a) dissolving the desired drug in an oil phase;
- b) formation of an oil/water emulsion;
- c) formation of a surface-active-antibody by chemical attachment of various hydrophobic groups to the antibodies;
- 5 d) mixing the surface-active antibody with the emulsion.

The present invention also relates to a method for drug targeting towards specific molecules or sites in the body (such as antigenic determinants), comprising admini-
10 stration to a host of an effective amount of pharmaceutical composition according to claim 1.

Description of the Invention

The invention is based on a simple process, which may
15 be applied to various types of drugs.

As described in Fig. 1, the final composition contains oil emulsion droplets onto which native or chemically modified antibodies are adsorbed. A hydrophobic drug is dissolved or solubilized inside the oil droplet, and there-
20 fore, the drug may be targeted to specific sites by the antibodies. The following principle steps are required for obtaining the final composition:-

1. Chemical attachment of various hydrophobic groups to the antibodies. This step will lead to formation of a
25 "surface-active-antibody".

2. Formation of an O/W emulsion by various simple methods which are well established. The oil phase initially contains the desired drugs.

3. Mixing the "surface-active-antibody" with the
30 emulsion, for a short period of time. The resulting composition is demonstrated in Fig. 1.

This process is very simple and may be applied rapidly to various types of drugs, antibodies, and emulsions. The
35 main advantages of the proposed method are:-

1. The process is very versatile and is based on a modular approach, which may be adopted by the final user,

provided the drug has a suitable solubility in the emulsion droplets, or may be dispersed or solubilized in the oil phase.

2. It is possible to use various types of oils for preparation of the emulsion to meet the requirement of drug solubility or dispersion.

3. The drug molecules are not subjected to any chemical modification; the original drug is maintained through the whole process.

4. Due to its hydrophobicity, the drug will not leak significantly from the oil droplets upon storage.

5. Desorption of the antibodies is a very unlikely event since the antibody has become a "surface-active-antibody" with improved adsorption capability; more protein molecules are adsorbed more strongly to the oil-water interface, than the native antibody.

6. The chemical modification of the antibodies is very simple and is performed in such a way that the biological activity and antigen recognition is not affected.

7. The same process may be applied to other biologically active substances which have a recognition capability.

8. The same process may be applied even without modification of the antibody by the use of specific molecules such as protein A.

9. The same process may be applied by physical attachment of hydrophobic groups to the antibody without covalent bonding.

10. The emulsion droplets serve as large reservoirs for drugs, and by the antibodies it is possible to obtain high local drug concentration without side effects.

Manner and Process of Making the Invented Composition

The apparatus and materials disclosed herein are merely exemplary, and after understanding the method, other embodiments may be devised.

Step I: Emulsion Preparation

1. The desired drug is dissolved or dispersed in the oil phase, which might be soybean oil, medium chain triglycerides (MCT) or any other oil, with increased or
5 decreased polarity and hydrophobicity. The oil may contain additions such as solubilizers, dispersants, etc.
2. An emulsifier (such as lecithin and pluronic F-68, or a combination of emulsifiers) is dissolved in an aqueous phase.
- 10 3. The oil phase is dropwise added to the aqueous phase while stirred by a mechanical or magnetic stirrer.
4. The crude emulsion is further homogenized until the desired droplet size is achieved. This step may be carried out by various instruments, such as polytron
15 (Brinkman Instruments), ultra-torex (Jumble & Kundel), high pressure piston homogenizers, microfluidizer, etc. The whole process for preparation of the emulsion may take less than half an hour. Typical composition contains about 20% W/W oil phase, 1-5% emulsifiers and water or saline up to
20 100%.

Step II: Antibody Modification

The desired antibody (monoclonal or polyclonal) is coupled to a hydrophobic tail by a simple chemical
25 reaction. During this step some parameters may vary such as the ratio of hydrophobic tails to antibody molecules and the length of the hydrophobic tail. It is important to note that only a slight modification is needed to impose surface activity without decreasing the biological activity.

30 The process described here is based on the use of active esters of fatty acids, but other methods may also be applied, and also physical adsorption of various groups. The principle steps are:-

1. Formation of N-alkanoyl succinimide ester (active
35 ester) by reacting a fatty acid (chain lengths C8-C18) with N-hydroxy succinimide, as described by Lapidot et al. [J. Lipid Research, 8, 142 (1967)].

2. Mixing the active ester with a solution of the desired antibodies, and formation of alkanoyl antibody, as described by Huang et al. [J. Biological Chem., 235, 8015-8018 (1980)].

5 3. Purification of the modified antibody by dialysis and/or Sephadex column.

The whole process is simple and requires no special equipment. The reaction conditions are chosen in such a way that the biological activity will not be affected, as will
10 be described in the examples.

Step III: Antibody-Emulsion Interaction

Since the modified antibodies are very surface active, all is needed for their adsorption onto emulsion droplet is
15 simple mixing for about one hour.

The modified antibody solution may be mixed with various volumes of the emulsion. (In some cases it is also possible to mix native and modified antibodies before the adsorption take place.)

20 After the adsorption process is completed, the final composition is achieved. This composition contains strongly attached antibodies at the oil-water interface and is capable of recognizing specific sites such as virally infected cells or cancer cells, depending on the type of
25 antibody used.

Examples

1. Modification of IgG with N-caproyl ester was conducted at various ester/IgG ratios. The resulting
30 antibodies were surface-active, having various numbers of attached hydrophobic groups.

After modification was completed, the biological activity was analyzed by quantitative evaluation of the active antibodies against Herpes Simplex Virus by two
35 methods:

Elisa, and fluorescence antibody assay labeling virally infected cells. From the results presented in Fig.

2 it is clear that up to a molar ratio of 4:1, the
recognition activity is not affected. The same results are
obtained from the recognition of virally infected BSC-1
cells, as presented in Fig. 3. Similar results were
5 obtained for infected Daudi cells (from human origin).

2. A series of modified and native antibodies were
adsorbed onto hydrophobic silica particles in order to
evaluate the increase in the surface activity. As shown in
10 Fig. 4, the amount of adsorbed antibody increases with the
increase of the ratio ether/antibody.

3. The hydrophobic particles, which have adsorbed
antibodies, were subjected to several washings with
15 Phosphate Buffer Saline (PBS) in order to evaluate their
desorption. As shown in Fig. 5, the native antibody is
readily desorbed while almost no desorption was detected
for the modified antibodies.

20 4. A series of native and modified IgG were adsorbed
on O/W water emulsions, and their effective activity was
evaluated. Emulsion compositions was 10% W/W soybean oil,
2% W/O lipoid PC and 88% W/W phosphate buffer saline. The
adsorption process is based on mixing 1 ml emulsion with
25 7.3 mg antibody and PBS up to a final volume of 19 ml. The
ingredients were gently mixed for 12 hrs at 37°C. The
detection of activity was achieved by addition of FITC
labeled anti IgG (H+C), mixing and reading the fluorescence
after adsorption. It is clear that if the modified IgG will
30 lose its activity, no fluorescence will be detected on the
emulsion droplets. The results obtained by a computerized
fluorescence microscope indicated, as shown in Fig. 6, that
enhancement of activity is indeed obtained with IgG which
was modified at a low ester/antibody ratio.

35

5. The attachment of the antibody may be achieved by
adsorption of protein A to the emulsion droplet. This could

lead to selective adsorption of the antibody with its Fab fragments facing the external aqueous phase. The new system: emulsion-protein A(native or modified)-antibody is a unique modular and versatile system in which no preparations are needed for each drug-antibody combination.

6. The purpose of the following example is to demonstrate the targeting of emulsion droplets to specific cells by in-vitro experiments.

An oil-in-water emulsion containing an oil soluble fluorescent marker was prepared. Onto this emulsion a modified antibody was adsorbed. (The antibody was modified by attachment of C₁₈ residues of fatty acid, 10% of the total available amine groups.)

The emulsion which contained the adsorbed antibody was added to two plates (30 minutes) which were covered by either normal BSC-1 cells, or BSC-1 cells which were previously infected by Herpes virus (HSV-1). After rinsing the plates it was found by a fluorescence microscope and also by ordinary microscope that emulsion droplets (coated with antibodies) were found only on the infected cells, as presented in Fig. 7.

As a control, a similar experiment was conducted, but without adsorbed antibodies. After rinsing the plates, emulsion droplets were not detected at all.

This example shows that the emulsion droplets having adsorbed antibodies against Herpes virus could be attached specifically onto Herpes infected cells.

CLAIMS:

1. Pharmaceutical compositions containing an oil/water emulsion wherein a drug is dissolved or dispersed or solubilized inside the oil droplets and wherein said emulsion droplets are coated with adsorbed native and/or modified antibodies.
2. Pharmaceutical compositions according to claim 1 wherein the oil phase is soybean oil, medium chain triglycerides or any other oil with increased or decreased polarity and hydrophobicity.
3. Pharmaceutical compositions according to claim 1 wherein the drug is hydrophobic.
4. Pharmaceutical compositions according to claim 1 wherein the drug is useful for cancer chemotherapy, inflammations, and infectious diseases including fungi and viral infections.
5. A process for the preparation of pharmaceutical compositions as defined in claim 1 comprising:-
 - a) dissolving or dispersing the desired drug in an oil phase;
 - b) formation of an oil/water emulsion;
 - c) formation of a surface-active-antibody by chemical or physical attachment of various hydrophobic groups to the antibodies;
 - d) mixing the surface-active antibody with the emulsion
6. A method for drug targeting towards specific molecules or sites in the body, comprising administration to a host of an effective amount of pharmaceutical composition according to claim 1.

1/4

Figure 1





Figure 2



2/4

Figure 3





Figure 4



3/4

Figure 5





Figure 6






Figure 7: Emulsion droplets attached to HSV infected BSC-1 cells, Gia surface active antibodies.

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/EP 94/02577

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 634 681 (IVAR GIAEVER ET AL.) 6 January 1987 see column 2, line 23 - line 31; claims ---	1,6
X	DATABASE WPI Week 8807, Derwent Publications Ltd., London, GB; AN 88-045802 & JP,A,63 002 923 (MIZUSHIMA) 7 January 1988 see abstract --- -/--	1-6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

* & * document member of the same patent family

Date of the actual completion of the international search

19 December 1994

Date of mailing of the international search report

30.12.94

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

Intern: al Application No
PCT/EP 94/02577

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Week 8848, Derwent Publications Ltd., London, GB; AN 88-341492 & JP,A,63 253 021 (MIZUSHIMA) 20 January 1988 see abstract</p>	1-6
A	<p>JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), vol.255, no.17, 10 September 1980, BALTIMORE, MD US pages 8015 - 8018 ANTHONY HUANG ET AL. 'MONOCLONAL ANTIBODY COVALENTLY COUPLED WITH FATTY ACID.' cited in the application see coupling of antibody with palmitic acid. see page 8015, column 2</p>	1,5
A	<p>EP,A,0 391 369 (YISSUM RESEARCH DEV. COMP. OF THE HEBREW UNIVERSITY OF JERUSALEM.) 10 October 1990 see page 5, paragraph 8; claim 1</p>	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 94/02577

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4634681	06-01-87	NONE	
EP-A-0391369	10-10-90	AT-T- 110563	15-09-94
		AU-B- 614465	29-08-91
		AU-A- 5292790	11-10-90
		CA-A- 2013755	05-10-90
		DE-D- 69011922	06-10-94
		JP-A- 2290809	30-11-90
		US-A- 5364632	15-11-94